Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain

With less than 50% of patients responding to the current standard of care and poor efficacy and selectivity of current treatments, neuropathic pain continues to be an area of considerable unmet medical need. Biological therapeutics such as monoclonal antibodies (mAbs) provide better intrinsic select...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicol, Louise S.C., Thornton, Peter, Hatcher, Jon P., Glover, Colin P., Webster, Carl I., Burrell, Matthew, Hammett, Kessia, Jones, Clare A., Sleeman, Matthew A., Billinton, Andrew, Chessell, Iain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828377/
https://www.ncbi.nlm.nih.gov/pubmed/29351125
http://dx.doi.org/10.1097/j.pain.0000000000001130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828377/
https://www.ncbi.nlm.nih.gov/pubmed/29351125
http://dx.doi.org/10.1097/j.pain.0000000000001130

Ejemplares similares